The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system

Print
Published on Friday, 30 September 2016

Abstract

The pineal hormone, melatonin, was examined for its capacity to modulate the proliferation of a panel of human breast cancer cell lines.

Melatonin inhibited, to a varying extent, the proliferation of all three estrogen-responsive cell lines, but had no effect on estrogen-insensitive breast tumor cell lines.

Melatonin was also able to specifically block estrogen-induced proliferation in MCF-7 breast cancer cells.

However, this action was abolished in the presence of tamoxifen.

Therefore, it appears that the antiproliferative effects of melatonin are mediated through the estrogen-response pathway.

 

 

About this publication.

 

See also:

- About Melatonin;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonisn, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma.